Literature DB >> 21189429

Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus.

Shokufeh Bonakdaran1, Maryam Hami, Mohammad Taghi Shakeri.   

Abstract

INTRODUCTION. Hyperuricemia is an independent risk factor for kidney dysfunction in diabetic patients. On the other hand, albuminuria is considered as the proxy of early stages of diabetic nephropathy. We investigated the correlation between hyperuricemia and albuminuria in patients with diabetes mellitus. MATERIALS AND METHODS. In a cross-sectional study of 1275 patients (555 men and 720 women) with type 2 diabetes mellitus, serum uric acid and urinary albumin-creatinine ratio were determined. Other metabolic parameters including lipid profile, hemoglobin A1c, glomerular filtration rate, body mass index, blood pressure, blood glucose were assessed, as well. RESULTS. The mean age of the patients was 52.45 ± 10.11 years old. Serum uric acid levels for normoalbuminuric, microalbuminuric, and macroalbuminuric patients were 4.49 ± 1.22 mg/dL, 4.84 ± 1.52 mg/dL, and 6.15 ± 1.68 mg/dL, respectively. Among patients with clinical metabolic syndrome, 233 (27.5%) were in the forth upper quartile of uric acid level (> 5.3 mg/dL), but in diabetic patients without this syndrome, only 80 (18.7%) were in this group. There was a significant relationship between hyperuricemia and serum triglyceride, fasting blood glucose, hemoglobin A1c, glomerular filtration rate, and serum creatinine levels (P < .001). No significant correlation was found between hyperuricemia and cholesterol levels, age, duration of diabetes mellitus, and body mass index. Serum uric acid level correlated positively with urinary albumin-creatinine ratio (P = .04). CONCLUSIONS. We showed that higher serum uric acid concentrations were associated with a greater probability of albuminuria in patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21189429

Source DB:  PubMed          Journal:  Iran J Kidney Dis        ISSN: 1735-8582            Impact factor:   0.892


  8 in total

1.  Association of uric acid, atherogenic index of plasma and albuminuria in diabetes mellitus.

Authors:  Emin Murat Akbas; Aysu Timuroglu; Adalet Ozcicek; Fatih Ozcicek; Levent Demirtas; Adem Gungor; Nergis Akbas
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review.

Authors:  G Zoppini; G Targher; E Bonora
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

3.  Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

Authors:  Damayanthi Devineni; Nicole Vaccaro; Joe Murphy; Christopher Curtin; Rao N V S Mamidi; Sveta Weiner; Shean-Sheng Wang; Jay Ariyawansa; Hans Stieltjes; Ewa Wajs; Nicholas A Di Prospero; Paul Rothenberg
Journal:  Int J Clin Pharmacol Ther       Date:  2015-02       Impact factor: 1.366

4.  Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus.

Authors:  Munisamy-Naidu Vinuthinee-Naidu; Embong Zunaina; Anuar Azreen-Redzal; Naing Nyi-Nyi
Journal:  BMC Ophthalmol       Date:  2017-06-14       Impact factor: 2.209

5.  Study of association of serum uric acid with albuminuria and carotid atherosclerosis in type 2 diabetes mellitus patients.

Authors:  Kuldeep Singh; Pardeep Kumar; Arun Joshi; Dileep Kumar Shivhare; Subodh Kumar Mahto; Akanskha Singh; Ankita Aneja; Brinder Mohan Singh Lamba
Journal:  J Family Med Prim Care       Date:  2019-12-10

6.  The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort.

Authors:  Lieneke Scheven; Michel M Joosten; Paul E de Jong; Stephan J L Bakker; Ron T Gansevoort
Journal:  J Am Heart Assoc       Date:  2014       Impact factor: 5.501

7.  Markers of Antioxidant Defense in Patients with Type 2 Diabetes.

Authors:  K Gawlik; J W Naskalski; D Fedak; D Pawlica-Gosiewska; U Grudzień; P Dumnicka; M T Małecki; B Solnica
Journal:  Oxid Med Cell Longev       Date:  2015-11-10       Impact factor: 6.543

8.  Harnessing electronic health records to study emerging environmental disasters: a proof of concept with perfluoroalkyl substances (PFAS).

Authors:  Mary Regina Boland; Lena M Davidson; Silvia P Canelón; Jessica Meeker; Trevor Penning; John H Holmes; Jason H Moore
Journal:  NPJ Digit Med       Date:  2021-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.